VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Shares

HENDERSON, Nev., July 28, 2022 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multinational epigenetics company, today announced that it has launched a public subscription offering of its common stock. All Common Shares are offered by Volition. In addition, Volition intends to grant the subscriber under the offer a 30-day option to purchase up to an additional 15% of the number of common shares offered under the offer at the price of public offering, less discounts and subscription fees. The final terms of the proposed offer will depend on market and other conditions, and there can be no assurance whether or not the offer will be completed, or as to the actual size or terms of the offer.

Newbridge Securities Corporation is acting as sole bookrunner for the offering.

The securities are offered by Volition pursuant to a “pending” registration statement on Form S-3 (File No. 333-259783) previously filed with the Securities and Exchange Commission (the “SEC”) on September 24, 2021 and declared effective by the SEC on November 8, 2021. The offering is made only by means of a prospectus supplement and accompanying base prospectus, which may be supplemented by any free written prospectus and/or supplement pricing that the Company may file with the SEC. A preliminary prospectus supplement and an accompanying base prospectus describing the terms of the proposed offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying base prospectus relating to the offering may also be obtained, when available, from Newbridge Securities Corporation, Attn: Equity Syndicate Department, 1200 North Federal Highway, Suite 400, Boca Raton, Florida 33432, by email at [email protected], or by phone at (877) 447-9625. The final terms of the offering will be disclosed in a final prospectus supplement that will be filed with the SEC.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, and there will be no sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Will

Volition is a multinational epigenetics company that applies its Nucleosomics™ platform across its subsidiaries to develop simple, easy-to-use and cost-effective blood tests to help diagnose and monitor a range of life-changing diseases, including certain cancers and diseases. associated with NETosis such as sepsis and COVID-19. Early diagnosis and follow-up have the potential not only to prolong patients’ lives, but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluids, an indication that disease is present. Volition primarily focuses on human diagnostics and monitoring, but also has a subsidiary focused on animal diagnostics and monitoring.

Volition’s research and development activities are centered on Belgiumwith an innovation lab and office in the United States and additional offices in London and Singapore.

Louise Batchelor/Debra DaglichWill
[email protected]
+44 (0)7557 774620

Scott PowellWill
[email protected]
+1 (646) 650 1351

Joseph GreenEdison Advisors
[email protected]
+1 (646) 653 7030

Caution Regarding Forward-Looking Statements

Statements contained in this press release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which relate to matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements reflect the current beliefs and expectations of management and include statements regarding the timing, size and anticipated gross proceeds of the offering, the satisfaction of customary closing conditions associated with the offering and sale of securities, the grant to the subscriber of an option to purchase additional shares and Volition’s ability to carry out the offer. All statements other than statements of historical fact are statements that could be considered forward-looking statements. Although Volition believes that the expectations reflected in these forward-looking statements are reasonable, it cannot guarantee that these expectations will prove to be correct. Forward-looking statements are subject to risks and uncertainties that may cause Volition’s actual operations or results to differ materially from those indicated or implied by any forward-looking statement, including, without limitation, due to risks and uncertainties relating to market conditions and the satisfaction of closing conditions relating to the proposed public offering, the risks disclosed in the section titled “Risk Factors” included in the preliminary prospectus supplement filed with the SEC on July 2022, and risks disclosed in other documents Volition files from time to time with the SEC, including Volition’s Quarterly Reports on Form 10-Q and its Annual Report on Form 10-K. Forward-looking statements are made as of the date of this release and, except as required by law, Volition does not undertake to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its affiliates.

SOURCE VolitionRx Limited

Comments are closed.